Jaguar Health, Inc. (JAGX)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Jaguar Health Soars 32% as Rare-Disease Pipeline News Meets Thin Post-Split Float
A rare-disease pipeline update and a thin post-split float are combining to send Jaguar Health (NASDAQ:JAGX) sharply higher. Jaguar Health stock is up 32% to $9.32 in morning trading, a surge rooted in company-specific forces.
Viking Therapeutics Sinks 15% After Pricing Upsized $500M Offering; Jaguar Health Tumbles 25%
Two biotech names are moving sharply lower Thursday morning while the sector benchmark grinds higher, a split move that puts the day's action on the companies themselves rather than on any broader rotation.
Two Biotechs Get Beaten Down: Jaguar Health Collapses 59%, Viking Therapeutics Sinks 4%
Two biotechnology names are lower in Wednesday morning trading for unrelated reasons, and the biotechnology sector itself isn't selling off. Jaguar Health (NASDAQ:JAGX) stock is at $14.
Jaguar Health, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Christopher C. Powers Farther Finance Advisors, LLC | 251 | $1,128 | $1,152.09 | $24.09 | 2.14% |
Jaguar Health, Inc. (JAGX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Jaguar Health, Inc. ever had a stock split?
Jaguar Health, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Lisa A. Conte CEO | NASDAQ (CM) Exchange | 47010C862 CUSIP |
| US Country | 47 Employees | 7 Jun 2019 Last Dividend | 17 Sep 2026 Last Split | 13 May 2015 IPO Date |
Overview
Jaguar Health, Inc. is a commercial-stage pharmaceutical company focused on developing innovative prescription medicines aimed at treating gastrointestinal distress, including chronic and debilitating diarrhea, in both humans and animals. Operating through two key segments—Human Health and Animal Health—the company seeks to address vital medical needs in underserved areas. Founded in 2013, Jaguar Health, Inc. has its headquarters in San Francisco, California, underlining its strategic positioning within a hub of biotechnological innovation and advancement.
Products and Services
- Mytesi:
A flagship product of Jaguar Health, Inc., Mytesi is a non-opioid, plant-based prescription medicine approved for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS who are on antiretroviral therapy. It represents a significant advancement in addressing the gastrointestinal side effects associated with long-term HIV treatment.
- Crofelemer:
Crofelemer is currently in a Phase 3 clinical trial phase and showcases Jaguar Health's commitment to expanding its gastrointestinal product portfolio. It is being developed for various indications, such as the prophylaxis of diarrhea in adult cancer patients undergoing specific treatments, and for rare or orphan diseases like Short bowel syndrome with intestinal failure, congenital diarrheal disorders, inflammatory bowel diseases, diarrhea-predominant irritable bowel syndrome, and idiopathic or functional diarrhea. This broad application underlines the versatility and potential of Crofelemer in addressing diverse gastrointestinal challenges.
- NP-300:
NP-300 represents Jaguar's effort in developing a second-generation anti-secretory antidiarrheal drug. Aimed at providing symptomatic relief and treatment for moderate-to-severe diarrhea, NP-300 is a testament to the company's ongoing research and development activities to produce innovative gastrointestinal solutions.
- Canalevia:
A unique oral, plant-based drug candidate designed specifically for the animal health segment. Canalevia is currently being developed to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea. This reflects Jaguar Health's commitment to addressing the health needs of animals, recognizing the impact of such conditions on their well-being and the need for effective, non-opioid treatments.
Contact Information
